BIO Logo

Bio-Rad Laboratories Inc (BIO) Stock Forecast & Price Prediction

Live BIO Stock Price & Analysis

Home โ€บ Stocks โ€บ United States | NYSE | Healthcare | Medical Devices

$346.03

-7.08 (-2.01%)

12 Month Price Forecast For BIO

$346.03
Current Price
$9.71B
Market Cap
6 Ratings
Buy 4
Hold 2
Sell 0
Wall St Analyst Ratings

Distance to BIO Price Forecasts

+37.8%
To High Target of $477.00
+18.5%
To Median Target of $410.00
-9.0%
To Low Target of $315.00

BIO Price Momentum

-3.6%
1 Week Change
+0.7%
1 Month Change
+6.5%
1 Year Change
+5.3%
Year-to-Date Change
-10.8%
From 52W High of $387.99
+32.0%
From 52W Low of $262.12

๐Ÿค” Considering Bio-Rad (BIO)?

Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.

Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.

Data last updated: February 5, 2025 8:59 PM UTC

BIO Analyst Ratings & Price Targets

Based on our analysis of 7 Wall Street analysts, BIO has a consensus that is bullish. The median price target is $410.00, with forecasts ranging from $315.00 to $477.00. Currently, there are 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings.

With BIO currently trading at $346.03, the median price forecast suggests a 18.5% upside. The most optimistic forecast comes from at , projecting a 37.8% upside, while at Jefferies provides the most conservative target, suggesting a -9.0% downside.

Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.

BIO Analyst Consensus

4
Buy
2
Hold
0
Sell

BIO Price Target Range

Low
$315.00
Average
$410.00
High
$477.00
Current: $346.03

Latest BIO Stock Forecasts by Analyst

These are the latest 20 analyst ratings and price targets for BIO.

Date Firm Analyst Rating Change Price Target
Jan 14, 2025 RBC Capital Conor McNamara Outperform Reiterates $481.00
Dec 9, 2024 RBC Capital Conor McNamara Outperform Maintains $481.00
Oct 31, 2024 Citigroup Patrick Donnelly Buy Maintains $450.00
Oct 31, 2024 RBC Capital Conor McNamara Outperform Maintains $469.00
Oct 1, 2024 Citigroup Patrick Donnelly Buy Upgrade $400.00
Aug 27, 2024 Wells Fargo Brandon Couillard Equal-Weight Initiates $340.00
Aug 16, 2024 RBC Capital Conor McNamara Outperform Reiterates $401.00
Aug 2, 2024 RBC Capital Conor McNamara Outperform Maintains $401.00
Aug 2, 2024 Citigroup Patrick Donnelly Neutral Maintains $350.00
Jun 3, 2024 Jefferies Hold Assumes $315.00
May 8, 2024 UBS Dan Leonard Buy Maintains $385.00
Apr 3, 2024 Citigroup Patrick Donnelly Neutral Downgrade $365.00
Feb 16, 2024 UBS Dan Leonard Buy Maintains $420.00
Feb 16, 2024 RBC Capital Conor McNamara Outperform Maintains $480.00
Dec 7, 2023 UBS Dan Leonard Buy Initiates $395.00
Aug 7, 2023 Wells Fargo Dan Leonard Overweight Maintains $525.00
Aug 4, 2023 RBC Capital Conor McNamara Outperform Maintains $524.00
Aug 4, 2023 Credit Suisse Dan Leonard Outperform Maintains $550.00
Jun 16, 2023 Wells Fargo Dan Leonard Overweight Initiates $550.00
May 8, 2023 RBC Capital Conor McNamara Outperform Maintains $531.00

Stocks Similar to Bio-Rad Laboratories Inc

The following stocks are similar to Bio-Rad based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.

Bio-Rad Laboratories Inc (BIO) Financial Data

Bio-Rad Laboratories Inc has a market capitalization of $9.71B with a P/E ratio of -16.0x. The company generates $2.58B in trailing twelve-month revenue with a -30.2% profit margin.

Revenue growth is +2.8% quarter-over-quarter, while maintaining an operating margin of +9.9% and return on equity of -9.8%.

Valuation Metrics

Market Cap $9.71B
Enterprise Value $9.65B
P/E Ratio -16.0x
PEG Ratio 29.7x
Price/Sales 3.8x

Growth & Margins

Revenue Growth (YoY) +2.8%
Gross Margin +54.8%
Operating Margin +9.9%
Net Margin -30.2%
EPS Growth +514.7%

Financial Health

Cash/Price Ratio +16.7%
Current Ratio 6.1x
Debt/Equity 18.5x
ROE -9.8%
ROA +1.9%

๐Ÿ”ฅ Want More High-Potential Stock Ideas?

Join 5,000+ investors getting our research on stocks with massive upside potential.

Bio-Rad Laboratories Inc logo

Bio-Rad Laboratories Inc (BIO) Company Overview

About Bio-Rad Laboratories Inc

What They Do

Manufactures life science and diagnostic products.

Business Model

The company operates through two segments: Life Science and Clinical Diagnostics. It generates revenue by developing, manufacturing, and marketing a wide range of instruments, systems, reagents, and consumables used in the separation and analysis of biological materials, as well as test systems and quality controls for medical laboratories.

Additional Information

Founded in 1952 and headquartered in Hercules, California, the company serves various markets including proteomics, genomics, and food safety, distributing products through a direct sales force and various intermediaries across multiple regions globally.

Company Information

Sector

Healthcare

Industry

Medical Devices

Employees

7,700

CEO

Mr. Norman D. Schwartz

Country

United States

IPO Year

1980

Bio-Rad Laboratories Inc (BIO) Latest News & Analysis

BIO stock latest news image
Quick Summary

Bio-Rad Laboratories, Inc. will report Q4 and full-year 2024 financial results on February 13, 2025, after market close, with a conference call at 2 PM PT.

Why It Matters

Bio-Rad's upcoming financial results announcement may impact stock prices and investor sentiment, revealing performance trends and future guidance critical for decision-making.

Source: Business Wire
Market Sentiment: Neutral
BIO stock latest news image
Quick Summary

BIO's strong performance in ddPCR technology and growth in clinical diagnostics suggests positive prospects for investors.

Why It Matters

BIO's strong ddPCR platform performance and clinical diagnostics growth signal potential revenue increases, enhancing investor confidence and possibly driving stock value.

Source: Zacks Investment Research
Market Sentiment: Positive
BIO stock latest news image
Quick Summary

Geneoscopy has secured $105 million in a Series C funding round, with Bio-Rad Laboratories as the lead investor.

Why It Matters

Geneoscopy's $105 million funding boosts its financial strength, signaling potential growth and innovation, which could positively impact stock performance and market confidence in biotech investments.

Source: Business Wire
Market Sentiment: Neutral
BIO stock latest news image
Quick Summary

Bio-Rad Laboratories' executives will meet with analysts and investors at J.P. Morgan's 43rd Annual Healthcare Conference in San Francisco from January 13-16, 2025.

Why It Matters

Bio-Rad's leadership meetings at a major healthcare conference signal potential strategic updates and insights, influencing investor sentiment and stock performance.

Source: Business Wire
Market Sentiment: Neutral
BIO stock latest news image
Quick Summary

Bio-Rad Laboratories (NYSE: BIO, BIO.B) will hold one-on-one meetings with analysts and investors at Citi's 2024 Global Healthcare Conference on December 3-5, 2024.

Why It Matters

Bio-Rad's leadership engaging with analysts at a major healthcare conference signals potential insights into company performance and strategy, which can influence stock valuations and investor sentiment.

Source: Business Wire
Market Sentiment: Neutral
BIO stock latest news image
Quick Summary

Bio-Rad's overseas revenue trends are influencing Wall Street forecasts and the company's stock outlook, impacting investor sentiment and potential growth.

Why It Matters

Bio-Rad's overseas revenue trends can influence earnings forecasts, impacting stock performance and investor sentiment regarding future growth potential.

Source: Zacks Investment Research
Market Sentiment: Neutral

Frequently Asked Questions About BIO Stock

What is Bio-Rad Laboratories Inc's (BIO) stock forecast for 2025?

Based on our analysis of 7 Wall Street analysts, Bio-Rad Laboratories Inc (BIO) has a median price target of $410.00. The highest price target is $477.00 and the lowest is $315.00.

Is BIO stock a good investment in 2025?

According to current analyst ratings, BIO has 4 Buy ratings, 2 Hold ratings, and 0 Sell ratings. The stock is currently trading at $346.03. Always conduct your own research and consider your investment goals before making investment decisions.

What is the price prediction for BIO stock?

Wall Street analysts predict BIO stock could reach $410.00 in the next 12 months. This represents a 18.5% increase from the current price of $346.03. Please note that this is a projection by Wall Street analysts and not a guarantee.

What is Bio-Rad Laboratories Inc's business model?

The company operates through two segments: Life Science and Clinical Diagnostics. It generates revenue by developing, manufacturing, and marketing a wide range of instruments, systems, reagents, and consumables used in the separation and analysis of biological materials, as well as test systems and quality controls for medical laboratories.

What is the highest forecasted price for BIO Bio-Rad Laboratories Inc?

The highest price target for BIO is $477.00 from at , which represents a 37.8% increase from the current price of $346.03.

What is the lowest forecasted price for BIO Bio-Rad Laboratories Inc?

Price targets from Wall Street analysts for BIO are not currently available. The stock is trading at $346.03.

What is the overall BIO consensus from analysts for Bio-Rad Laboratories Inc?

The overall analyst consensus for BIO is bullish. Out of 7 Wall Street analysts, 4 rate it as Buy, 2 as Hold, and 0 as Sell, with a median price target of $410.00.

How accurate are BIO stock price projections?

Stock price projections, including those for Bio-Rad Laboratories Inc, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.